NEW YORK (TheStreet) -- Gentium (GENT), Concord Medical Services (CCM), Nektar Therapeutics (NKTR), Dendreon (DNDN), ShangPharma (SHP), Teva Pharmaceutical (TEVA), WuXi PharmaTech (WX), Elan (ELN), Celgene (CELG), and Par Pharmaceutical (PRX) are expected to return up to 72%, based on their respective 12-month price targets.
Health care stocks had underperformed in the last one year due to uncertainty over the federal health care policy and ailing European economies. In the last one year, while the S&P 500 INDEX returned 11%, the S&P Global Health Care Sect. (ETF) notched up only 5.6%. However, 2011 is shaping up well, as the health care sector tracked broader indices rising 6% since the start of the year compared to 5.6% for the broader index. The proposed health care spending cuts announced by Barak Obama during the week did not weigh heavily on the sector. Relatively lower volatility of stock performance compared to broader indices and a pick-up in M&A activity in the sector augurs well for the sector.
Going ahead, the global health care market could get a boost on growing medical expenditure in emerging countries. Rising income levels and improved growth rates could increase public and private spending on health care. The demand for high-technology medical devices will likely expand going forward, benefiting the relevant U.S. companies. An aging population and public health insurance could sustain demand in the developed countries.
We have identified 10 stocks which, according to analysts, could outperform their peers and broader market indices. These stocks have an upside potential of 20% to 72% with a mean upside value of around 40% and average buy ratings of 80%.In comparison, pharma giants Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY) and Eli Lilly (LLY) have upsides of -2% to 14%, according to analysts' estimates.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV